Correlations between amantadine usage, gait, and cognition in PSP: a post hoc analysis of the davunetide trial
Objective: Amantadine anecdotally improves gait and balance in PSP, potentially by increasing alertness, but there are no definitive data to support this observation. We investigated…Parkinsonism, delayed chorea and dystonia caused by extrapontine myelinolysis
Objective: To describe two case reports of patients with movement disorders due to extrapontine myelinolysis. Background: Central Pontine Myelinolysis (CPM) and Extra pontine myelinolysis (EPM)…High dose amantadine therapy may cause increased falling in Parkinson’s patients
Objective: To report a possible association between high dose amantadine and increased falling in patients with Parkinson’s disease (PD). Background: Amantadine is used in PD…Randomized, placebo-controlled, double-blind, two-period cross-over study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for levodopa induced dyskinesia in Parkinson’s Disease (BUS-PD)
Objective: To evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). Background: LID is…The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program
Objective: To assess the impact of Gocovri® (amantadine) extended release capsules on motor aspects of experiences of daily living in PD patients. Background: Gocovri is…Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product
Objective: To demonstrate the unique shape and pharmacokinetic (PK) profile of Gocovri® (amantadine) extended release (ER) capsules by using metrics pertinent to ER dosage forms.…Gocovri Dose Adjustment in Elderly Parkinson’s Patients at Risk for Renal Impairment: Implications from an Exposure Simulation Model
Objective: Evaluate amantadine exposure following Gocovri® (amantadine) extended release capsules dosing regimens in renal impairment, using pharmacokinetic (PK) modeling and simulations. Background: Gocovri bedtime dosing…The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program
Objective: To assess patient outcomes and adverse events in Parkinson’s disease (PD) patients treated with Gocovri® (amantadine) extended release capsules at bedtime for dyskinesia, by…Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study
Objective: To explore amantadine IR utilization patterns in the French COPARK study. Background: Immediate release (IR) amantadine is marketed for the treatment of early and…Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data
Objective: To assess the real-world safety profile of Gocovri® (amantadine) extended release capsules one year post-launch. Background: Gocovri received FDA approval in August 2017 for…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.